1. Scrip
  2. >>Business
  3. >>Earnings

2017 Pharma Sales: A New Global Order

 
• By John Hodgson

As the reality of annual results arrive, Scrip predicts how the top of the pharma league table is likely to change.

Podium
Who had the biggest pharma revenue in 2017?

The last week in January and the first week in February are full of surprises. They bring the financial results of all the top 15 pharmaceutical companies (except those of Bayer AG, which arrive at the end of February). The circus started on Jan. 23 with news from Johnson & Johnson that its pharma sales hit $36.3bn, up 8.3% from 2016, over half of the increase being due to its mid-year acquisition of Actelion.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.

Novartis $23bn US Investment Is Music To Trump’s Ears

 
• By Kevin Grogan

The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.